Results 311 to 320 of about 2,849,098 (354)

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

The Lancet, 1999
T. Möttönen, P. Hannonen, M. Leirisalo-Repo, M. Nissilä, H. Kautiainen, M. Korpela, L. Laasonen, H. Julkunen, R. Luukkainen, K. Vuori, L. Paimela, H. Blåfield, M. Hakala, K. Ilva, U. Yli-Kerttula, K. Puolakka, P. Järvinen, M. Hakola, H. Piirainen, J. Ahonen, Ilppo Pälvimäki, S. Forsberg, K. Koota, C. Friman   +23 more
semanticscholar   +1 more source

COMBINED DRUG THERAPY FOR OVARIAN CARCINOMA

Clinical Obstetrics and Gynecology, 1970
M C, Li, K P, Hsu
openaire   +2 more sources

[Combination drug therapy in leprosy].

Acta leprologica, 1984
The importance of polichemotherapy in multibacilar leprosy (LL and LD) in patients without any previous therapy as in those diagnosticated and under monotherapy most of all in the resistance patients is presented. Sulphones, clofazimine and rifampicine are selected as first rate drugs and protionamide-etionamide as second rate drugs.
openaire   +1 more source

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.

European Urology, 2013
C. Füllhase, C. Chapple, J. Cornu, C. de Nunzio, C. Gratzke, S. Kaplan, M. Marberger, F. Montorsi, G. Novara, M. Oelke, H. Porst, C. Roehrborn, C. Stief, K. McVary   +13 more
semanticscholar   +1 more source

Combination therapy for kidney disease in people with diabetes mellitus

Nature Reviews Nephrology
D. V. van Raalte, P. Bjornstad, D. Cherney, I. D. de Boer, P. Fioretto, D. Gordin, Frederik Persson, Sylvia E. Rosas, P. Rossing, J. Schaub, Katherine R. Tuttle, S. Waikar, Hiddo J. L. Heerspink   +12 more
semanticscholar   +1 more source

Hybrid drug combination: Combination of ferulic acid and metformin as anti-diabetic therapy.

Phytomedicine, 2017
Rakesh P. Nankar, Pranav Kumar Prabhakar, M. Doble   +2 more
semanticscholar   +1 more source

Hodgkin lymphoma: A review and update on recent progress

Ca-A Cancer Journal for Clinicians, 2018
Satish P Shanbhag, Richard F Ambinder
exaly  

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

Arthritis & Rheumatism, 2008
M. Genovese, J. McKay, E. Nasonov, E. Mysler, N. A. da Silva, E. Alecock, T. Woodworth, J. Gómez-Reino   +7 more
semanticscholar   +1 more source

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Lancet, The, 2015
Andreas H Diacon, Robert Schall, Prudence Ive   +2 more
exaly  

The application of prodrug-based nano-drug delivery strategy in cancer combination therapy.

Colloids and Surfaces B: Biointerfaces, 2016
Yanxiu Ge, Yakun Ma, Lingbing Li
semanticscholar   +1 more source